ArticleFrontiers in immunology2022

Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.

Melinda Ahmels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.